Dapagliflozin: first SGLT2 inhibitor for type 2 diabetes

Dapagliflozin (Forxiga) is the first SGLT2 inhibitor licensed for the treatment of type 2 diabetes. In our New products review, Steve Chaplin presents the clinical data relating to its efficacy and adverse events, and Professor John Wilding discusses its potential role in treatment.

Dapagliflozin first SGLT2 inhibitor for type 2 diabetes

Add yours ↓
Web design and marketing agency Leamington Spa